New cancer drug trial halted early – only 16 patients tested
NCT ID NCT07529535
First seen Apr 21, 2026 · Last updated May 20, 2026 · Updated 6 times
Summary
This early-stage trial tested a new drug called ALK-N001 in 16 people with advanced solid tumors, including esophageal and lung cancers. The main goal was to check safety and find the right dose. The study was suspended, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCE SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Zhejiang Cancer Hospital
Hangzhou, 310022, China
-
Zhongshan Hospital, Fudan University
Shanghai, 200032, China
Conditions
Explore the condition pages connected to this study.